← Back to Search

PrEPTECH website for HIV/AIDS (PrEPTECH2 Trial)

N/A

Waitlist Available

Led By Bhupendra Sheoran, MBBS, MBA

Research Sponsored by ETR Associates

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3-months post enrollment and 6 months post enrollment

Awards & highlights

PrEPTECH2 Trial Summary

This trial is designed to assess the effectiveness of a telehealth intervention in increasing PrEP uptake among 400 cisgender men and transgender women who have sex with men over six months, by measuring self-reported PrEP initiation rates at 3 months post-enrollment.

Eligible Conditions

HIV/AIDS
Pre-Exposure Prophylaxis
Telemedicine

PrEPTECH2 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3-months post enrollment and 6 months post enrollment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3-months post enrollment and 6 months post enrollment

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3-months post enrollment and 6 months post enrollment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Secondary outcome measures

PrEP coverage at 3 months post-enrollment

PrEP coverage at 6 months post-enrollment

PrEP medication prescription, observed

+11 more

PrEPTECH2 Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: PrEPTECH intervention recipientsExperimental Treatment1 Intervention

The intervention is a web site delivering access to PrEP telehealth. The platform provides access to laboratory testing for PrEP eligibility delivered to a participant's home, telehealth care and PrEP prescriptions for those eligible delivered asynchronously through an online form for all adult participants and through telephone appointments for adolescent participants, and a mail-order pharmacy for PrEP. Additionally, free PrEP medication will be provided through the intervention. Transgender female and adolescent cisgender male participants will receive free PrEP medication (emtricitabine [200 mg]/tenofovir disoproxil fumarate [300 mg]) for the duration of their participation in the study, while adult cisgender male participants will receive a free 30-day supply of PrEP and subsequently have to pay for PrEP medication through insurance, patient assistance programs, or out of pocket.

Group II: Control resource-list only recipientsActive Control1 Intervention

Participants will receive access to an online list of web-based resources about PrEP and how to locate and pay for PrEP care and contact information for a professional PrEP navigator at a local community-based organization partnering with the study.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

ETR AssociatesLead Sponsor

11 Previous Clinical Trials

9,918 Total Patients Enrolled

Bhupendra Sheoran, MBBS, MBAPrincipal InvestigatorETR

Rebecca Braun, DrPH, MPHPrincipal InvestigatorETR

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this study include participants aged 18 or older?

"As per the criteria outlined, only individuals aged between 15 and 27 are eligible for this trial. 65 trials were conducted with participants below fifteen years old; conversely 208 trials have been completed by those over sixty-five."

Answered by AI

Are researchers still taking partakers for this experiment?

"According to the clinicaltrials.gov listing, this medical investigation is actively searching for suitable candidates. This project was originally posted on February 12th 2022 and revised on February 18th 2022."

Answered by AI

What is the current capacity of this clinical research initiative?

"Affirmative. The information found on clinicaltrials.gov shows this study is currently searching for potential candidates to enrol. This trial was first posted on February 12th 2022 and the details were recently updated on February 18th 2022, with 400 participants needed from a single site."

Answered by AI

For whom is this clinical trial suitable?

"Eligible participants must have access to telemedicine and be between 15-27 years old. This study is expected to enroll up to 400 patients in total."

Answered by AI

Recent research and studies

JAIDS Journal of Acquired Immune Deficiency SyndromesJournal

Brief Report: Preptech: A Telehealth-based Initiation Program for HIV Pre-exposure Prophylaxis in Young Men of Color Who Have Sex with Men. A Pilot Study of Feasibility

Refugio, Oliver N., Mabel M. Kimble, Cara L. Silva, James E. Lykens, Christian Bannister, and Jeffrey D. Klausner. 2019. “Brief Report: Preptech: A Telehealth-based Initiation Program for HIV Pre-exposure Prophylaxis in Young Men of Color Who Have Sex with Men. A Pilot Study of Feasibility”. JAIDS Journal of Acquired Immune Deficiency Syndromes. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/qai.0000000000001873.

clinicaltrials.govStudy

PrEPTECH Phase 2 Study of a PrEP Telehealth Intervention

2022. "PrEPTECH Phase 2 Study of a PrEP Telehealth Intervention". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04902820.